Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.72 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24099251 | 0.90 | MTNR1A (0.61) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2790131 | 0.86 | MTNR1A (0.74) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29759426 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3508630 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12648555 | 0.84 | MTNR1A (0.69) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1778456 | 0.83 | MTNR1A (0.66) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29868708 | 0.83 | MTNR1A (0.66) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30444072 | 0.83 | HDAC1 (0.71) | HDAC1 | |
| SCHEMBL13436463 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6764471 | 0.82 | NQO2 (0.74) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| CN-114026080-A | Conjugates containing compounds providing a pi-electron pair | 阿森迪斯药物股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| CN-112641767-A | New application of synephrine | 昆明理工大学 | 2021-04-13 | — | — | CN | disclosed |
| CN-111035637-A | Application of N-acetyl-5-methoxy tryptamine, and related composition and culture medium | 艾尔瑞斯贸易公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | MTNR1A 3104/4885MTNR1B 2778/4885CYP1A2 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.